Most importantly, genetic and pharmacologic inhibition of the GSK3B-53BP1 signaling axis dramatically enhances the cytotoxic response of cancer in vitro and in vivo to PARP inhibitors (PARPi) independent of BRCA1 status. This evidence concerns the gene TP53BP1 and cancer.